期刊
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
卷 113, 期 4, 页码 219-226出版社
ELSEVIER TAIWAN
DOI: 10.1016/j.jfma.2014.01.002
关键词
angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers; chronic kidney disease; pentoxifylline; renal outcome
资金
- National Science Council [102-2314-B-002-027-MY3]
- Mrs Hsiu-Chin Lee Kidney Research Foundation
Background/Purpose: Several studies have shown the renoprotective effects of pentoxifylline in the treatment of chronic kidney disease (CKD). This study was conducted to examine whether there was an increased benefit of including pentoxifylline with angiotensinconverting enzyme inhibitor (ACEI) or angiotensin ll receptor blacker (ARB) in the treatment of CKD. Methods: A single-center retrospective analysis was conducted. A total of 661 Stage 3B-5 CKD patients who received ACEI or ARB treatment were recruited. The patients were divided into the pentoxifylline use group and the no pentoxifylline group. Renal survival analysis of the two groups was compared. Subgroup analysis was performed by dividing the patients into lower [urine protein to creatinine ratio (UPCR) < 1 g/g] and higher (UPCR >= 1 g/g) proteinuria subgroups. Results: There was no between-groups difference regarding mortality and cardiovascular events. Addition of pentoxifylline showed a better renal outcome (p = 0.03). The protective effect of add-on pentoxifylline was demonstrated in the higher proteinuria subgroup (p = 0.005). In the multivariate Cox regression model, pentoxifylline use also showed a better renal outcome [hazard ratio (HR): 0.705; 95% confidence interval (CI): 0.498-0.997; p = 0.048]. This effect was more prominent in the higher proteinuria subgroup (HR: 0.602; 95% CI: 0.413-0.877; p = 0.008). Conclusion: In the advanced stages of CKD, patients treated with a combination of pentoxifylline and ACEI or ARB had a better renal outcome than those treated with ACEI or ARB alone. This effect was more prominent in the higher proteinuria subgroup. More large randomized control trials are needed to provide concrete evidence of the add-on effect of pentoxifylline. Copyright (C) 2014, Elsevier Taiwan LLC Et Formosan Medical Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据